Correction: GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025
Thorsten Simon(University of Cologne), Angelika Eggert(MSB Medical School Berlin), Julian M.M. Rogasch(Charité - Universitätsmedizin Berlin), Friederike Körber(University Hospital Cologne), Hedwig E. Deubzer(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Johannes H. Schulte(German Cancer Research Center), Beate Timmermann(Essen University Hospital), Peter Lang(STZ eyetrial), Matthias Fischer(University of Cologne), Danny Jazmati(Düsseldorf University Hospital), Thorsten Langer, Carolina Rosswog(University of Cologne), Jochen Hubertus(Marien Hospital Witten), Kathy Astrahantseff(Essen University Hospital), Steven W. Warmann(University Children's Hospital Tübingen), Barbara Hero(University Hospital Cologne), Matthias Schmidt(University Hospital Cologne), S Castelli(Humboldt-Universität zu Berlin), Christian Vokuhl(University Hospital Schleswig-Holstein), Jörg Fuchs(University Children's Hospital Tübingen), Rudolf Schwarz(Universität Hamburg), Theresa Thole(Charité - Universitätsmedizin Berlin), Jürgen Schäfer(University Children's Hospital Tübingen), Holger N. Lode(Universitätsmedizin Greifswald)
Cited by 1
Related Papers
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
|Journal of Clinical Oncology|2005|654
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563